[
  {
    "The following situations are generally inappropriate for MGUS/paraproteinemia eConsult [PLEASE PLACE AN IN-PERSON REFERRAL INSTEAD]": [
      "Unexplained anemia, cardiomyopathy, bone pain/fractures, hepatosplenomegaly, hypercalcemia, lytic lesions, macroglossia, nephrotic syndrome/proteinuria, renal insufficiency, neuropathy, purpura, B symptoms",
      "M-protein > 1.5 g/dL",
      "Isolated FLC ratio > 8",
      "IgA MGUS"
    ]
  },
  {
    "My Clinical Question (condition: MGUS/paraproteinemia)": "***"
  },
  {
    "My most current assessment of this problem can be found in the note dated": "{Today/***}"
  },
  {
    "In your clinical question, or current note, please include information on": {
      "Assessments": {
        "Required": [
          {
            "Documentation of a complete ROS and Physical Examination (see criteria inappropriate for e-consult)": "***"
          }
        ],
        "Optional": []
      },
      "Diagnostics": {
        "Required": [
          {
            "CBC with diff": "***"
          },
          {
            "CMP": "***"
          },
          {
            "SPIE": "***"
          },
          {
            "Serum free light chain ratio": "***"
          },
          {
            "UPEP (if SPIE or FLC ratio is abnormal)": "***"
          },
          {
            "Quantitative Immunoglobulins (if SPIE or FLC ratio is abnormal)": "***"
          },
          {
            "Random urine protein-creatinine ratio and microalbumin-creatinine ratio (if UPEP ordered)": "***"
          }
        ],
        "Optional": []
      },
      "Clinical Pearls": [
        {
          "The sensitivity of screening for paraproteinemia is up to 98% combining the serum protein electrophoresis, serum protein immunofixation, and serum free light chain assay.": "***"
        },
        {
          "Classical “CRAB criteria” are hypercalcemia, renal insufficiency, anemia, or bone lesions": "***"
        },
        {
          "If M-spike < 1.5 g/dL, IgG subtype, K/L ratio is normal, then they meet criteria for low-risk MGUS. Repeat labs in 6 months and if stable, then annual labwork for paraproteinemia is recommended for patients. Laboratory surveillance can be discontinued for patients with a life expectancy of <5 years and among those >80 years old. The risk of progression for MGUS is usually at most 1% per year to a symptomatic plasma cell proliferative disorder or lymphoproliferative disorder": "***"
        }
      ]
    }
  }
]
